NINT Distinguished Lecture Series

Thinking Big with Nano

Frustration and the Joy of Invention: Groups C and B Meningococcal Vaccine Design

  • Date: Wednesday, July 15, 2015
  • Time: 2:15 pm (Coffee and cookies at 2:00 pm)
  • Location: NINT Taylor Room, 11421 Saskatchewan Drive

Meningococcal meningitis is a devastating disease with extremely high mortality and morbity rates. Currently, vaccines to prevent disease acquisition, with the exception of group B, consist of the capsular polysaccharides of the meningococci, which function well in aduits but do not prevent disease in infants who are the most vulnerabie to this disease. By chemically linking the group C polysaccharide to tetanus toxoid, a conjugate vaccine was produced which was used in the UK to successfully control an epidemic of group C meningococcal meningitis in the UK in 2000. The group B meningococca polysaccharide is not a good vaccine for adults or infants. However, chemical modification (N-propionylation) of the group B polysaccharide prior to its iinkage to tetanus toxoid has resulted in a potential conjugate vaccine for human use.

Everyone is welcome!

nint_awards_20141106NINT Awards

A wide range of activities are eligible for nomination, and any member of the NINT community is eligible for any of the awards. To nominate somebody (or yourself), simply fill out the nomination form with the nominee’s name, award category, and a brief description of how you think this individual merits the award. It is anonymous and will go directly to the NINT awards committee.

NRC_1914NINT supports interdisciplinary collaboration in strategically important areas of nanotechnology by creating a unique environment that merges the best of the university knowledge creation culture with the best of the strategic and focused problem solving culture of a national laboratory to ensure responsible and effective introduction of nanotechnology to the benefit of Canada.